Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Increasing Flu Vaccination Through Evidence-Based Nudges (INFLUENCE)

10 de novembro de 2026 atualizado por: Elena Azzolini, Istituto Clinico Humanitas

Nudge-based Strategies to Increase Influenza Vaccination Uptake Among Health and Social Care Personnel: a Multicentre Cluster-randomised Trial

This study aims to find out whether changing the wording and content of workplace emails can encourage more healthcare and non-healthcare staff to get a seasonal flu vaccine. The main question is whether emails that highlight the benefits of vaccination, the possible consequences of not getting vaccinated, or vaccination rates among colleagues are more effective than standard information emails.

The study will take place during the 2026-2027 flu vaccination campaign across 17 healthcare and social care organizations in Lombardy, Italy. Approximately 45,000 eligible workers are expected to be included, covering both staff who provide patient care and those in administrative, technical, and support roles.

Workplace groups, such as departments or organizational units, are randomly assigned to one of four email communication approaches:

  • Standard information (control): emails communicating that the vaccination campaign is ongoing and that it is possible to get vaccinated.
  • Benefits of vaccination (gain framing): emails emphasizing the potential benefits of vaccination for workers, patients, colleagues, and the organization.
  • Consequences of not getting vaccinated (loss framing): emails emphasizing the possible risks and negative consequences for workers, patients, colleagues, and the organization.
  • Vaccination among colleagues (social norms): emails and follow-up updates showing vaccination progress and, where possible, comparing vaccination rates in the recipient's workplace group with those in other groups.

Researchers will use existing vaccination and employment records to compare the percentage of workers who receive a flu vaccine in each group by the end of the campaign. They will also examine whether the emails encourage earlier vaccination and whether their effects differ across workplaces and staff groups. Where suitable records are available, they will explore differences in sickness absence during the campaign.

Vaccination will remain voluntary, and all workers will continue to have access to the usual vaccination services. The study involves workplace emails and the use of existing records; no additional medical visits, tests, or procedures are required.

The findings will help healthcare organizations decide whether simple changes to routine communication can improve staff flu vaccination rates and which approach works best.

Visão geral do estudo

Descrição detalhada

Seasonal influenza represents a major public health issue, associated with morbidity, mortality, pressure on healthcare services, workforce absenteeism and risk of transmission in care settings. Influenza vaccination of healthcare and non-healthcare workers employed in healthcare and social care organisations is an important preventive measure, not only for individual protection, but also for the indirect protection of frail patients, reduction of transmission in healthcare settings, preservation of continuity of care and resilience of healthcare services. Despite the availability of influenza vaccination and public health recommendations, vaccination uptake among healthcare and non-healthcare workers remains suboptimal and variable across organisations, professional profiles and organisational units. Communication strategies informed by behavioural science, commonly referred to as "nudges", represent low-cost, scalable organisational interventions that may guide individuals towards preventive behaviours while preserving individual autonomy. The study aims to evaluate the effectiveness of an organisational and behavioural communication strategy with potential impact on prevention, quality of care pathways, workforce resilience and public health.

Primary objective: to evaluate the effectiveness of nudge-based communication strategies, assigned at organisational cluster level, in increasing influenza vaccination uptake among eligible healthcare and non-healthcare workers during the 2026-2027 influenza vaccination campaign compared with standard institutional communication.

Secondary objectives:

  • to compare the relative effectiveness of the different communication arms, including standard communication, gain framing, loss framing and social norms/peer feedback;
  • to assess the change in influenza vaccination uptake during the 2026-2027 campaign compared with the 2025-2026 campaign, where historical data are available; to evaluate time to vaccination;
  • to explore heterogeneity of effect by organisational cluster, healthcare/non-healthcare area and previous vaccination history, where available;
  • to assess sickness absence indicators at cluster level during the vaccination campaign, where such data are available and comparable across participating organisations;
  • to generate evidence to inform future organisational, regional and potentially national vaccination communication and prevention policies.

Primary endpoint:

Influenza vaccination uptake during the 2026-2027 influenza vaccination campaign, defined as the proportion of eligible healthcare and non-healthcare workers within the randomised clusters who receive influenza vaccination by the end of the observation period. Documented vaccinations will be considered irrespective of the setting in which they are administered, including vaccinations administered within the participating organisation or through other authorised vaccination pathways, where captured by ARVAX or other applicable regional administrative data sources.

Secondary endpoints:

  • Absolute percentage-point change in influenza vaccination uptake between the 2026-2027 campaign and the 2025-2026 campaign, at cluster level;
  • Time to vaccination, defined as the number of days between delivery of the communication assigned to the cluster and the documented date of influenza vaccination;
  • Sickness absence indicators at cluster level during the vaccination campaign, including number of sickness absence days and/or sickness absence rates standardised by eligible population or person-time, according to data availability and quality.

Population and patient selection criteria: The study population consists of healthcare and non-healthcare workers eligible for influenza vaccination during the 2026-2027 campaign and belonging to organisational clusters included in the study within the 17 participating Lombardy organisations.

In this protocol, the term "patients/subjects" should be understood as "study participants/workers", since the study is not conducted on assisted patients. Inclusion criteria: employment or affiliation with one of the 17 participating organisations; belonging to an included and randomised organisational cluster; eligibility for influenza vaccination according to applicable regional/organisational recommendations; availability in administrative data flows required to define the denominator; and availability of vaccination outcome data through administrative, regional or organisational data sources.

Exclusion criteria: non-eligibility for influenza vaccination; lack of minimum data required for denominator definition, cluster attribution or outcome ascertainment; belonging to clusters that are not classifiable, mappable or randomizable; termination of employment/affiliation before the start of the campaign if not exposed to the possibility of organisational vaccination; or any other administrative condition preventing correct attribution to cluster, study arm or outcome.

Study design: This is a pragmatic, multicentre, four-arm, parallel-group, cluster-randomised, non-pharmacological procedural-organisational interventional study, prospectively implemented during the 2026-2027 influenza vaccination campaign. Randomisation will occur at the level of organisational clusters, defined as organisational units uniformly identified across participating centres according to FLUPER or another consistent organisational classification available within the participating organisations. Clusters will be allocated in a 1:1:1:1 ratio to one of four arms: standard communication, gain framing, loss framing, and social norms/peer feedback. Outcomes and denominators will be assessed using routinely available administrative, regional and organisational data flows, including FLUPER, the regional healthcare workforce administrative flow used to support workforce denominator definition and organisational classification, and ARVAX, the regional vaccination registry/database used to ascertain vaccination uptake; where available, organisational workforce or human resources data flows used to assess cluster-level sickness absence indicators will be used.

Description of the intervention: The intervention consists of institutional e-mail communications sent by the Vaccination Unit or the competent organisational function of each participating organisation, with content differentiated according to the study arm assigned to the cluster.

  • Arm 1 - Standard communication: standard e-mail containing information on the launch of the influenza vaccination campaign, access procedures, vaccination sites, opening hours and booking channels.
  • Arm 2 - Gain framing: e-mail emphasising the benefits of vaccination for the worker, patients, colleagues and the organisation.
  • Arm 3 - Loss framing: e-mail emphasising the risks and potential negative consequences of non-vaccination for the worker, patients, colleagues and the organisation.
  • Arm 4 - Social norms / peer feedback: periodic e-mails providing updates on campaign progress and, where feasible, comparison between the vaccination uptake rate of the recipient's cluster and that of other clusters or the overall cluster average.

The comparator is standard/informational communication, corresponding to routine communication on the launch of the vaccination campaign and on access procedures.

Number of participants planned: The overall expected number of participants will be determined based on FLUPER/organisational data flows and other available administrative sources from the 17 participating organisations before final randomisation. All eligible healthcare and non-healthcare workers belonging to the randomised clusters are expected to be included.

Total number planned: approximately 45,000 healthcare and non-healthcare workers across all 17 participating organisations, subject to confirmation based on the final eligible workforce denominator derived from FLUPER and/or organisational administrative data flows before randomisation. Number planned per arm: approximately one quarter of the overall eligible population, depending on the number and size of randomised cluster

Tipo de estudo

Intervencional

Inscrição (Estimado)

45000

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Bergamo, Itália
        • ATS Bergamo
      • Brescia, Itália
        • ASST Spedali Civili di Brescia
      • Crema, Itália
        • ASST Crema
      • Desenzano del Garda, Itália
        • ASST Garda
      • Garbagnate Milanese, Itália
        • ASST Rhodense
      • Legnano, Itália
        • ASST Ovest Milanese
      • Lodi, Itália
        • ASST Lodi
      • Milan, Itália
        • Istituto Europeo di Oncologia
      • Milan, Itália
        • ASST Fatebenefratelli-Sacco
      • Milan, Itália
        • ASST Santi Paolo e Carlo
      • Paderno Dugnano, Itália
        • Clinica Polispecialistica San Carlo
      • Pavia, Itália
        • ASST Pavia
      • Pavia, Itália
        • ATS Pavia
      • Sondrio, Itália
        • ASST Valtellina e Alto Lario
      • Treviglio, Itália
        • ASST Bergamo Ovest
      • Vimercate, Itália
        • ASST Brianza
    • Lombardy
      • Milan, Lombardy, Itália, 20089
        • Istituto Clinico Humanitas

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Filho
  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion criteria:

  • employment or affiliation with one of the 17 participating organisations;
  • belonging to an included and randomised organisational cluster;
  • availability in administrative data flows required to define the denominator;
  • availability of vaccination outcome data through administrative regional data sources.

Exclusion criteria:

  • lack of minimum data required for denominator definition, cluster attribution or outcome ascertainment;
  • belonging to clusters that are not classifiable, mappable or randomizable.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Prevenção
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Control

Standard communication: standard e-mail informing that the vaccination campaing is ongoing and inviting healthcare workers to participate.

Dear Colleague,

The seasonal flu vaccination campaign is underway.

If you have not yet been vaccinated, please remember that you can receive your vaccination by following the instructions previously provided.

Thank you for your attention and for contributing to this prevention effort.

Experimental: Gain Framing

Gain framing: e-mail emphasising the benefits of vaccination for the worker, patients, colleagues and the organisation.

Dear Colleague,

The seasonal flu vaccination campaign is underway.

Flu is not always a mild illness. Globally, it is estimated to cause 3-5 million cases of severe illness and 290,000-650,000 deaths associated with respiratory disease each year. In Italy, more than 21,000 hospital admissions each year are attributable to flu or related respiratory and cardiovascular complications.

Getting vaccinated against flu protects both individual and community health:

  • It reduces the spread of the flu virus, benefiting care recipients, patients, colleagues, and family members.
  • It reduces the risk of complications in people with chronic conditions.
  • It reduces the risk of a heart attack in the seven days following a confirmed flu infection.

If you have not yet been vaccinated, please remember that you can receive your vaccination by following the instructions previously provided.

Thank you for your attention and for contributing to this prevention effort.

Experimental: Loss framing

Loss framing: e-mail emphasising the risks and potential negative consequences of non-vaccination for the worker, patients, colleagues and the organisation.

Dear Colleague,

The seasonal flu vaccination campaign is underway.

Flu is not always a mild illness. Globally, it is estimated to cause 3-5 million cases of severe illness and 290,000-650,000 deaths associated with respiratory disease each year. In Italy, more than 21,000 hospital admissions each year are attributable to flu or related respiratory and cardiovascular complications.

Not getting vaccinated against flu increases both individual and community risks:

  • It increases the spread of the flu virus, affecting care recipients, patients, colleagues, and family members.
  • It increases the risk of complications in people with chronic conditions.
  • It increases the risk of a heart attack in the seven days following a confirmed flu infection.

If you have not yet been vaccinated, please remember that you can receive your vaccination by following the instructions previously provided.

Thank you for your attention and for contributing to this prevention effort.

Experimental: Social norms

Social norms: weekly e-mails providing updates on campaign progress and comparison between the vaccination uptake rate of the recipient's cluster and that of other clusters assigned to the same experimental arm.

Dear Colleague,

The seasonal flu vaccination campaign is underway.

To encourage staff vaccination, the Agency will send a brief weekly update on the campaign's progress from now through December. These updates will compare vaccination rates across selected organizational units within the Agency. The units were selected at random and were formed by grouping organizational structures with similar areas of activity.

If you have not yet been vaccinated, please remember that you can receive your vaccination by following the instructions previously provided.

Thank you for your attention and for contributing to this prevention effort.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Influenza vaccination uptake at the end of 2026-2027 campaign.
Prazo: Up to 6 months

Proportion of eligible healthcare and non-healthcare workers within the randomised clusters who receive influenza vaccination by the end of the observation period of the campaign.

Up to 6 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Influenza vaccination uptake at mid 2026-2027 campaign.
Prazo: Up to 3 months

Proportion of eligible healthcare and non-healthcare workers within the randomised clusters who receive influenza vaccination at mid of the campaign.

Up to 3 months
Change in influenza vaccination uptake between seasons.
Prazo: Baseline and 6 months

Absolute percentage-point change in influenza vaccination uptake between the 2026-2027 campaign and the 2025-2026 campaign.

Baseline and 6 months
Time to vaccination.
Prazo: Up to 6 months

The number of days between the delivery of the communication assigned to the cluster and the documented date of influenza vaccination.

Up to 6 months
Sickness absence.
Prazo: Up to 6 months

Number of sickness absence days and/or sickness absence rates standardised by eligible population or person-time.

Up to 6 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

21 de outubro de 2026

Conclusão Primária (Estimado)

31 de março de 2027

Conclusão do estudo (Estimado)

31 de março de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

30 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

10 de novembro de 2026

Primeira postagem (Real)

17 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

No IPD data will be collected as part of the study.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever